Overview

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Toripalimab combined with Anlotinib.
Phase:
N/A
Details
Lead Sponsor:
Third Military Medical University
Treatments:
Carboplatin
Cisplatin